The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

17:51 EST Vertex Pharmaceuticals (VRTX)’ non-opioid painkiller approved by FDA, Bloomberg says Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

17:55 EST Vertex Pharmaceuticals (VRTX) up 2% at $448 after FDA Journavx approval Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

For example, the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) share price is up 83% in the last five years, slightly above the market return. Over the last year the stock price is up ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

(Reuters) -The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to ... new tools come along in a long time," said Richard Rosenquist, chairman of the Pain Management ...

Shares of Vertex Pharmaceuticals VRTX5.31%increase; green up pointing triangle rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

As part of Vertex’s ongoing commitment to patients, the company has established patient support programs to help ensure that qualified patients can access JOURNAVX. For more information visit ...